Anti-tumour necrosis factor (TNF)-α therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis

Rheumatology

Volumn 41, Issue 5, 2002, Pages 484-489

  Catrina, A I ^a   Lampa, J ^a   Ernestam, S ^a   Af Klint, E ^a   Bratt, J ^a   Klareskog, L ^a   Ulfgren, A K ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Etanercept; Metalloproteinases; Rheumatoid arthritis; Soluble tumour necrosis factor receptor; Tissue inhibitors of metalloproteinases

Indexed keywords

C REACTIVE PROTEIN; CPH 82; CYCLOSPORIN; ETANERCEPT; INTERSTITIAL COLLAGENASE; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ANTIBODY SPECIFICITY; ARTICLE; BIOPSY; BLOOD LEVEL; CELL COUNT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; INDIVIDUALIZATION; JOINT DESTRUCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SYNOVIUM; TISSUE LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOWN-REGULATION; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; SYNOVIAL MEMBRANE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TREATMENT OUTCOME;

EID: 0036263676     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Anti-cytokine therapy for rheumatoid arthritis
2. Matrix metalloproteinases in tumour invasion and metastasis
3. Etiology and pathogenesis of rheumatoid arthritis
4. Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis
5. Elevated plasma stromelysin levels in arthritis
6. Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis
7. The measurement of collagenase, tissue inhibitor of metalloproteinases (TIMP), and collagenase-TIMP complex in synovial fluids from patients with osteo-arthritis and rheumatoid arthritis
8. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid other surrogate markers
9. Gene expression (collagenase, tissue inhibitor of metalloproteinases, complement and HLA-DR) in rheumatoid arthritis and osteo-arthritis synovium. Quantitative analysis and effect of intraarticular corticosteroids
10. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis
11. Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis
12. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy
13. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
14. Podophyllum derivatives (CPH 82) compared with placebo in the treatment of rheumatoid arthritis
15. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis
16. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials
17. Detection of cytokine producing cells in the synovial membrane from patients with rheumatoid arthritis
18. Interindividual and intra-articular variation of proinflammatory cytokines in patients with rheumatoid arthritis: Potential implications for treatment
19. Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis
20. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis
21. Serum matrix metalloproteinase-3 and fibrin degradation product levels correlate with clinical disease activity in rheumatoid arthritis
22. Early joint erosions and serum levels of matrix metalloproteinase (MMP)-1. MMP-3 and tissue inhibitor of metalloproteinase-1 (TIMP) in rheumatoid arthritis
23. Synovial tissue protease gene expression and joint erosions in early rheumatoid arthritis